Buck Elizabeth 4

What Happened

• Elizabeth Buck, Chief Scientific Officer of Black Diamond Therapeutics (BDTX), received a derivative award covering 250,000 shares on January 21, 2026. The award is reported at a price of $0.00 (no cash paid reported) and is classified as an acquisition/award (Form 4 code A).

Key Details

• Transaction date: 2026-01-21; Form 4 filed: 2026-01-23 (filed within typical 2-business-day window).
• Award size: 250,000 shares; reported price/exercise: $0.00.
• Shares owned after transaction: not specified in this filing.
• Footnote (vesting): 25% of the award vests on January 21, 2027; the remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• Transaction type: grant/award (derivative), not an open-market purchase or sale.

Context

• This is a compensation grant (derivative award) with a multi-year vesting schedule, so the shares are not immediately transferable or liquid. Such grants are routine for executives and reflect compensation arrangements rather than an outright market buy or sell.